PDS Biotechnology Corporation Common Stock (PDSB) is a publicly traded Healthcare sector company. As of July 27, 2026, PDSB trades at $0.68 with a market cap of $38.11M and a P/E ratio of -0.92. PDSB moved -2.63% today. Year to date, PDSB is -15.15%; over the trailing twelve months it is -43.69%. Its 52-week range spans $0.51 to $2.46. Analyst consensus is buy with an average price target of $15.00. Rallies surfaces PDSB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
PDS Biotechnology Extends Cash Runway to Q3 2027, Advances PDS0101 to Phase 2: PDS Biotechnology extended its cash runway into the third quarter of 2027 after completing a financing round in Q1 2026. The company advanced its lead immuno-oncology candidate PDS0101 into Phase 2 head-and-neck cancer trials with pembrolizumab, targeting interim efficacy readouts by late 2026.
| Metric | Value |
|---|---|
| Price | $0.68 |
| Market Cap | $38.11M |
| P/E Ratio | -0.92 |
| EPS | $-0.74 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.46 |
| 52-Week Low | $0.51 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-34.50M |
| Gross Margin | 0.00% |
1 analysts cover PDSB: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.00.